BAG3 and cancer: In fact recently, the first selective BAG domain modulator of BAG3 has been proposed as a novel candidate for the development of a new class of chemotherapeutic agents (Terracciano et al., 2018); this 2,4‐thiazolidinedione derivative, by interfering with the binding between BAG3 and Hsp70, reduces cancer cell proliferation.